INTERNATIONAL DIABETES FEDERATION CONSENSUS ON DEFINITION OF THE METABOLIC SYNDROME: FACTS AND COMMENTS
https://doi.org/10.20996/1819-6446-2009-5-6-47-50
Abstract
International Diabetes Federation consensus, devoted to definition of the metabolic syndrome was published in 2006. The main statements of this document are presented and commented.
About the Author
M. N. Mamedov
State Research Center for Preventive Medicine of Rosmedtechnology
Russian Federation
Petroverigsky per. 10, Moscow, 101990
Russian Federation
Petroverigsky per. 10, Moscow, 101990
References
1. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
2. Saad M.F., Lillioja S., Nyomba B.L. et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324(11):733-9.
3. Diabetes and Obesity: Time to Act. International Diabetes Federation (IDF) and International Association for the Study of Obesity (IASO), 2004.
4. Brunzell J.D., Ayyobu A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115 Suppl 8A:24S-28S..
5. Robins S.J., Rubins H.B., Faas F.H. et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26(5):1513-7.
6. Steinmetz A., Fenselau S., Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001:109(4):S548-59.
7. Lindstrom J., Louheranta A., Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
8. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16.
9. Haffner S.M., Alexander C.M., Cook T.J. et al. Reduced coronary events in simvaststin-treated patients with coronary heart disease and diabetes mellitus or impaired fasting glucose level: subgroup analysis on the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159(22):2661-7.
10. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh repot of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42(6): 1206-52.
11. Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.
12. Durbin R.J. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280-5.
13. Chiasson J.L., Josse R.G., Comis R. et al. Stop-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial. JAMA 2003;290(4):486-94.
14. Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomised study of orlistat as an adjunct to lifestyle changes for the preventionof type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
Review
For citations:
Mamedov M.N. INTERNATIONAL DIABETES FEDERATION CONSENSUS ON DEFINITION OF THE METABOLIC SYNDROME: FACTS AND COMMENTS. Rational Pharmacotherapy in Cardiology. 2009;5(6):47-50. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-6-47-50
Views:
899
Email this article 